Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s share price hit a new 52-week low on Monday . The stock traded as low as $1.52 and last traded at $1.57, with a volume of 187800 shares trading hands. The stock had previously closed at $1.62.

Several equities analysts have recently weighed in on the stock. ValuEngine lowered shares of Orexigen Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised shares of Orexigen Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research report on Monday, August 14th.

The company has a quick ratio of 1.71, a current ratio of 2.00 and a debt-to-equity ratio of -2.75.

Orexigen Therapeutics (NASDAQ:OREX) last released its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.35) EPS for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.78. Orexigen Therapeutics had a negative net margin of 192.65% and a negative return on equity of 824.15%. The business had revenue of $18.90 million for the quarter, compared to analyst estimates of $24.20 million. During the same period last year, the firm earned $1.12 earnings per share. Orexigen Therapeutics’s revenue for the quarter was up 170.0% compared to the same quarter last year. equities research analysts anticipate that Orexigen Therapeutics, Inc. will post -10.08 EPS for the current year.

An institutional investor recently raised its position in Orexigen Therapeutics stock. KCG Holdings Inc. increased its holdings in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) by 30.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 43,954 shares of the biopharmaceutical company’s stock after acquiring an additional 10,139 shares during the quarter. KCG Holdings Inc. owned about 0.29% of Orexigen Therapeutics worth $151,000 as of its most recent filing with the SEC. 34.69% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/04/orexigen-therapeutics-orex-sets-new-12-month-low-at-1-52.html.

Orexigen Therapeutics Company Profile

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Receive News & Stock Ratings for Orexigen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics Inc. and related stocks with our FREE daily email newsletter.